Relay Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
RLAY$19.94-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Par Value | Capital | (Loss)/Income | Deficit | Equity | |
| Balances at December 31, 2024 | 167,755,715 | $168 | $2,516,905 | $(991) | $(1,738,290) | $777,792 |
| Vesting of restricted stock units | 2,728,157 | — | — | — | — | — |
| Stock compensation expense | — | — | 19,325 | — | — | 19,325 |
| Unrealized gain on investments | — | — | — | 1,029 | — | 1,029 |
| Net loss | — | — | — | — | (77,065) | (77,065) |
| Balances at March 31, 2025 | 170,483,872 | $168 | $2,536,230 | $38 | $(1,815,355) | $721,081 |
| Issuance of common stock via employee stock purchase plan | 222,353 | — | 653 | — | — | 653 |
| Vesting of restricted stock units | 985,907 | — | — | — | — | — |
| Stock compensation expense | — | — | 14,500 | — | — | 14,500 |
| Unrealized loss on investments | — | — | — | (201) | — | (201) |
| Net loss | — | — | — | — | (70,375) | (70,375) |
| Balances at June 30, 2025 | 171,692,132 | $168 | $2,551,383 | $(163) | $(1,885,730) | $665,658 |
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Par Value | Capital | (Loss)/Income | Deficit | Equity | |
| Balances at December 31, 2023 | 127,462,409 | $127 | $2,152,654 | $(196) | $(1,400,582) | $752,003 |
| Issuance of common stock through Private Placement, net | 2,500,000 | 3 | 29,800 | — | — | 29,803 |
| Issuance of common stock via at-the-market offerings, net | 1,889,597 | 2 | 17,930 | — | — | 17,932 |
| Issuance of common stock through exercise of stock options | 236,367 | — | 1,187 | — | — | 1,187 |
| Vesting of restricted stock units | 212,478 | — | — | — | — | — |
| Stock compensation expense | — | — | 27,188 | — | — | 27,188 |
| Unrealized loss on investments | — | — | — | (962) | — | (962) |
| Net loss | — | — | — | — | (81,387) | (81,387) |
| Balances at March 31, 2024 | 132,300,851 | $132 | $2,228,759 | $(1,158) | $(1,481,969) | $745,764 |
| Issuance of common stock through exercise of stock options | 106,173 | 1 | 412 | — | — | 413 |
| Issuance of common stock via employee stock purchase plan | 203,818 | — | 1,129 | — | — | 1,129 |
| Vesting of restricted stock units | 714,112 | — | — | — | — | — |
| Stock compensation expense | — | — | 26,832 | — | — | 26,832 |
| Unrealized loss on investments | — | — | — | (182) | — | (182) |
| Net loss | — | — | — | — | (92,212) | (92,212) |
| Balances at June 30, 2024 | 133,324,954 | $133 | $2,257,132 | $(1,340) | $(1,574,181) | $681,744 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.